The efficacy and toxicity of sodium stibogluconate (SSG) at a dosage of 20 mg/(kgrd) for either 20 days (for cutaneous disease) or 28 days (for visceral, mucosal, or viscerotropic disease) in the treatment of leishmaniasis is reported. Ninety-six U.S. Department of Defense health care beneficiaries with parasitologically confirmed leishmaniasis were prospectively followed for 1 year. One patient was infected with human immunodeficiency virus; otherwise, comorbidity was absent. Clinical cure occurred in 91% of 83 cases of cutaneous disease and 93% of 13 cases of visceral/viscerotropic disease. Adverse effects were common and necessitated interruption of treatment in 28% of cases, but they were generally reversible. These included arthralgias and myalgias (58%), pancreatitis (97%), transaminitis (67%), headache (22%), hematologic suppression (44%), and rash (9%). No subsequent mucosal leishmaniasis was identified, and there were no deaths attributable to SSG or leishmaniasis.
Diagnostics, Aguada, Puerto Rico) stained touch preparation follow-up by telephone at 6 and 12 months sufficed unless they described a change in the skin lesion or persistent nasal or histopathologic section. Expandable cultures permitted identification of Leishmania species by cellulose acetate electrophosymptoms, in which case they were asked to return to WRAMC for evaluation. Fifty patients (52%) were contacted for longer resis for isoenzyme analysis, with comparison to World Health Organization reference strains [8, 9] . Patients were excluded follow-up to assess for late mucosal leishmaniasis or SSGrelated adverse events. if they had serious concomitant cardiac, renal, or hepatic disease, had a history of hypersensitivity to antimonials, or were pregnant. Prior pancreatitis was not exclusionary. The protocol
Definition of Clinical Cure
was approved by the WRAMC Human Use Committee and Leishmanial cutaneous ulcers were considered clinically Triservice Scientific and Ethical Review Committee.
cured if complete reepithelialization was evident by 2 months Cutaneous leishmaniasis was defined as chronic skin lefollowing the initiation of SSG treatment. Papulonodular or sion(s) with parasites visible by the methods noted above. Visverrucous cutaneous lesions were considered cured if they were cerotropic leishmaniasis was defined as a subacute illness assoflattened, were not indurated (unless a cicatrix or keloid had ciated with a positive leishmanial culture of a bone marrow formed), and showed no signs of new activity over the same or lymph node specimen. These patients typically have mild period. When initial improvement of lesions with therapy was symptoms, fairly normal physical examination findings, and followed by new ulcerative or infiltrative clinical findings after few laboratory abnormalities [10] . Visceral leishmaniasis was completion of SSG treatment, the lesions were considered to a constellation of fever, cytopenias, and hepatosplenomegaly have relapsed. Those lesions that did not completely reepitheliin association with parasites identified by biopsy of bone maralize by 2 months following initiation of treatment were considrow or gastrointestinal or splenic specimens.
ered nonresponders (partially responding to treatment [12] ). Treatment failure was defined by little response of skin lesions
Treatment and Follow-Up
to treatment (õ25% epithelialization). Viscerotropic leishmaniasis was considered cured if the maAfter enrollment in the study, patients were administered jority of symptoms diminished in temporal relationship with SSG at a dosage of 20 mg per kg (total body weight) per day.
SSG treatment and/or if culture of a bone marrow biopsy speciTreatment duration was 20 days for cutaneous leishmaniasis men at the end of treatment yielded no growth. Visceral leishor 28 days for visceral, mucosal, or viscerotropic leishmaniasis.
maniasis was considered to be clinically cured if symptoms From 1989 to 1994, SSG was given for 30 days for visceral resolved and if hepatosplenomegaly and hematologic parameor viscerotropic leishmaniasis. SSG was diluted in 50 mL of ters normalized by the 6-month follow-up. 5% dextrose in water and infused intravenously via a peripheral butterfly needle over 10 -15 minutes. Nine different lots of
Statistical Methods
Pentostam were used during this period.
Enrolled patients had a detailed history recorded and physical Data were abstracted from patient records with use of a examination performed initially and were seen by a physician standardized form. These data were doubly entered into a datadaily during therapy. Before-treatment and after-treatment phobase with the program Epi-Info (version 6; CDC), and descriptographs of cutaneous lesions documented response to therapy. tive data analyses were performed. In the calculation of effiElectrocardiograms were obtained on treatment days 0, 4, 7, cacy, the denominator included the total number of patients 14, and 20 (and 28 for visceral leishmaniasis). At baseline and who started SSG treatment. The numerator included the patwice weekly during therapy, urinalysis was performed and tients who were considered clinically cured and completed at the complete blood cell count (with differential) and levels least 10 days of treatment with SSG. of glucose, blood urea nitrogen, creatinine, electrolytes, total For statistical comparison of medians between groups of protein, albumin, calcium, phosphorus, lactate dehydrogenase, patients with cutaneous, visceral, and viscerotropic leishmaniatotal bilirubin, alkaline phosphatase, aspartate aminotransferase sis, the Kruskal-Wallis test was used. Proportions of treatment (AST), and alanine aminotransferase (ALT) were determined.
responders to nonresponders were compared with the twoAfter recognition of the frequent association between SSG tailed Fisher's exact test, and medians between these two therapy and pancreatitis [11] , serum amylase and lipase levels groups were compared with the Mann-Whitney U test. All P were monitored daily for the first week and twice weekly therevalues were considered significant at a level of P õ .05. after. Patients were asked to refrain from alcohol use during therapy to avoid potentiation of possible hepatic or pancreatic Results toxicity (defined as an AST, ALT, lipase, or amylase serum / 9c5c$$de22 11-11-98 16:48:50 cida UC: CID All patients were in excellent health at baseline, with the was not implemented. No patients were considered obese or significantly malnourished. exception of one patient with visceral leishmaniasis who had AIDS. Three HIV-negative patients with visceral leishmaniasis Daily unstructured physician interviews were conducted during therapy (table 4) . The most common symptoms were arwere children õ4 years of age; otherwise, the patients were young men. One patient with cutaneous leishmaniasis reported a history of unsuccessful meglumine antimoniate therapy; the remaining patients had no history of antimonial treatment. All Table 2 . Diagnostic findings in the study cases of leishmaniasis.
patients had traveled to an area in which Leishmania is known to be endemic. nosed by expert review of histopathology at the Armed Forces 3. An arbitrary absolute upper limit to the daily SSG dose / 9c5c$$de22 11-11-98 16:48:50 cida UC: CID thralgias and myalgias, which developed in the latter half of mg/d, developed a prolonged corrected Q-T interval (Q-Tc) of .551 on day 28. therapy. These complaints varied from mild discomfort to activity-limiting effects and were managed by the limiting of Laboratory abnormalities associated with SSG treatment were also analyzed (table 5). Pancreatic abnormalities tended physical exercise and use of nonsteroidal antiinflammatory agents. Abdominal pain, nausea, and vomiting were generally to occur very early in therapy and to decline despite continued SSG treatment. Our practice was to withdraw SSG if serum noted in the first week and were usually associated with elevated serum amylase and lipase levels. Most cutaneous reacamylase levels became ú4 times the ULN or lipase levels became ú15 times the ULN, regardless of symptoms. We tions were few, generalized, erythematous papules. Several patients had small vesicular, pruritic lesions on the palmar or resumed therapy once these values trended significantly toward normal levels [11] . Fifteen patients' serial serum triglyceride interdigital aspects of their hands. Four patients (4%) developed herpes zoster near the end of treatment or in the early convaleslevels were followed but were unremarkable. Elevations in transaminase levels tended to occur later in the treatment course cent period [14] .
Type of leishmaniasis
Electrocardiographic changes were noted in 20 patients than the pancreatic enzyme changes. SSG caused some hematologic toxicity. In viscerotropic or (21%), principally T-wave inversion or flattening in comparison with baseline findings. The patient with AIDS and visceral cutaneous leishmaniasis, peripheral blood cell counts declined during treatment. In one case thrombocytopenia (platelets, leishmaniasis, who was receiving SSG at a dosage of 1,640 46,000/mm 3 ) developed, necessitating discontinuation of SSG quired a third course of SSG. This patient had also been previously treated with meglumine antimoniate. The small number therapy. In contrast, with visceral disease, hematologic parameters often improved with therapy.
of clinical nonresponders limited the conclusions that can be drawn about them (table 7) . Nonresponders were treated with SSG therapy was interrupted (table 3) primarily for pancreatitis or musculoskeletal symptoms. In most cases, therapy was SSG from multiple lots. Since resistance in vitro has been identified after intermittent antimony exposure [15] , we anareinstituted after a brief (2 -5-day) hiatus without further incident. Therapy was terminated early for nine patients (9%).
lyzed the nonresponders for interrupted treatment courses (33%) and found no significant difference from the responders Three of 9 patients dropped out against medical advice: 1 left to join a combat mission and the other 2 left the hospital 1 (26%). Toxicity was increased during the second course of antiday before the last dose because of transportation problems. Two patients requested termination on day 14 and day 18, mony. Arthralgias were noted with earlier onset (day 2 -3). Two of five patients stopped the second course early, one berespectively, because of severe musculoskeletal symptoms. Three patients' therapy was stopped (on days 2, 3, and 12) for cause of musculoskeletal symptoms and the other for abdominal symptoms with elevated transaminase levels. Two patients symptomatic pancreatitis. One required support with parenteral hyperalimentation for 1 week.
had conjunctival edema and facial puffiness or swelling. Overall, 93 (97%) of the 96 patients were clinically cured with SSG, four required a second treatment course, and one
Clinical Outcome
even needed a third course. Two patients received only 2 -3 doses of SSG, and the likelihood of significant drug effect was Table 6 summarizes the results of SSG treatment. The IND protocol required a 1-year follow-up. However, to identify posquestionable in assessment of outcome, as they received no further therapy. sible late mucosal leishmaniasis and adverse effects of medication, longer-term follow-up was initiated; 85 (88%) of the patients were contacted, with an overall median follow-up of 1.3 Discussion years (range, 0 -9 years). During follow-up, no SSG-treated patient with New World cutaneous leishmaniasis developed
We determined the efficacy and toxicity of the SSG dosing regimen currently recommended for the treatment of leishmanimucosal leishmaniasis.
Three deaths occurred: 1 patient was killed in combat, 1 asis [4] . Since SSG is available in the United States under an IND protocol, requirements for monitoring its use are stringent. committed suicide 4 years after SSG treatment, and 1 died of AIDS complicated by toxoplasma encephalitis.
Most of our patients did not reside in areas of endemicity during follow-up, a circumstance decreasing the likelihood of Five patients (6%) showed some initial improvement but then relapsed (table 6) . Each was given a second 20-day course reinfection. The demographic characteristics of our patients were dicof SSG. Of the five patients treated with a second course of SSG, four (80%) were then clinically cured. One patient retated by exposures to Leishmania from military operations.
/ 9c5c$$de22 11-11-98 16:48:50 cida UC: CID Arabia (1990 Arabia ( -1992 . Consistent with these opportunities for exposure to Leishmania, most patients therapy is needed for cutaneous leishmaniasis.
In conclusion, we found SSG administered intravenously at were male infantry soldiers, Special Forces, Rangers, or SEAL team members. The predominance of whites (83%) in the leisha dosage of 20 mg/(kgrd) to have excellent efficacy in the treatment of nearly 100 patients with leishmaniasis. New World maniasis case population is somewhat higher than in the activeduty U.S. Army (62%) (personnel data from the Defense Mancutaneous leishmaniasis was most prevalent in our series, but visceral and viscerotropic leishmaniasis cases were also treated power data center). The distribution of Leishmania species identified in culture is consistent with previously published with good results. British and U.S. military experience [16 -21] .
Previous reports of SSG toxicity at a dosage of 20 mg/(kgrd) have been limited and varied [4, 12] . Reported symptoms have
